NAVIGATOR: avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour
Avapritinib shrank tumours in almost nine in ten patients with PDGFRA D842V-mutant gastrointestinal stromal tumour, a subtype completely resistant to imatinib and every other kinase inhibitor, and became its first effective treatment.
Overview
Phase 1 dose-escalation and expansion study; this analysis covers 56 patients with PDGFRA D842V-mutant advanced GIST treated with avapritinib at 300 or 400 mg daily.
Objective response was 88 percent (9 percent complete), median duration of response not reached, and 12-month progression-free survival 81 percent; cognitive effects, periorbital oedema and anaemia were the characteristic toxicities, with rare intracranial bleeding.
- Objective response 88 percent in PDGFRA D842V-mutant GIST.
- Twelve-month progression-free survival 81 percent.
Avapritinib 300 mg is the standard first-line treatment for advanced PDGFRA D842V GIST, and mutation testing before starting imatinib is essential to identify these patients.
- Single-arm; cognitive side effects need monitoring and dose adjustment.
- In non-D842V GIST avapritinib was not superior to regorafenib (VOYAGER).
Similar pages
not linked directly; found by shared links- TrialVOYAGER
Shares PDGFRA D842V-mutant GIST, Avapritinib.
- TermGIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)
Shares PDGFRA D842V-mutant GIST, Avapritinib.
- TargetPDGFRA
Shares PDGFRA D842V-mutant GIST, Avapritinib.
- TargetKIT
Shares PDGFRA D842V-mutant GIST, Avapritinib.
- CancerGastrointestinal stromal tumour (GIST)
Shares PDGFRA D842V-mutant GIST, Avapritinib.